Join the Viread group to help and get support from people like you.
Viread News
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir...
FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV
The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for...
U.S. Food and Drug Administration Approves New Formulations of Viread for Use by Children Living With HIV
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan 19, 2012 - Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread (tenofovir disoproxil fumarate) in...
FDA Medwatch Alert: Viread (tenofovir disoproxil fumarate)
Gilead Sciences, Inc. notified healthcare professionals of a high rate of early virologic failure and emergence of nucleoside reverse transcriptase inhibitor (NRTI) resistance associated mutations...
Ask a question
To post your own question to this support group, sign in or create an account.